Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?
The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.
How this was made
The 30-second read
Why it matters
Clorox’s Q4 beat and raised net sales growth guidance are the primary catalysts, reinforced by the GOJO acquisition. However, the gross margin decline and an adjusted EPS outlook that is still below some expectations introduce downside risk to the bull case.
Market read
Traders get a consolidated view of the post-earnings guidance, acquisition support, and the Street’s mixed stance, which can drive near-term positioning around consensus expectations.
What to watch
Analyst positioning is mixed (Hold consensus with multiple Strong Sells), so traders may focus on whether the acquisition integration and margin recovery are credible rather than the headline sales growth beat.
Background
The piece frames Clorox’s recent underperformance versus the S&P 500 and compares it to the consumer staples ETF, then pivots to the Aug. 3 Q4 results and subsequent analyst stance.
Ticker impact
Clorox shares jumped after Q4 results and raised fiscal 2027 net sales growth guidance to 13% to 14%, plus EPS outlook.
Likely supports a bullish bias versus the prior analyst stance, but upside may be capped by the weaker gross margin and the still-subdued adjusted EPS range.
The article cites a concrete earnings/guidance update (net sales growth 13% to 14%, Q4 sales and EPS beats) and a major acquisition (GOJO), while also noting gross margin down 520 bps and adjusted fiscal 2027 EPS guidance of $5.70 to $6.00.
Market effects
Consumer staples read-through may improve modestly if Clorox’s health and wellness demand and international growth are seen as resilient.
Limited, as the catalyst is company-specific rather than a broad regional macro shock.
International segment growth guidance could marginally influence sentiment toward global consumer staples demand, but the article is not a cross-market macro signal.
Counterpoint
The stock’s upside may fade because adjusted fiscal 2027 EPS guidance remains below analysts’ and gross margin fell sharply, implying cost pressure that could outweigh demand strength.
Key entities
- companyClorox Company
Subject of the article, with Q4 2026 results, fiscal 2027 guidance, and analyst rating/price-target updates.
- companyGOJO Industries
Acquired by Clorox for $2.25 billion, supporting the forward narrative in health and wellness.
- financial_institutionJPMorgan
Raised its Clorox price target to $95 while keeping an Underweight rating.
- etfState Street Consumer Staples Select Sector SPDR ETF
Used as a benchmark for relative performance versus Clorox over 52 weeks.
